Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/157559
Author(s): Hites, M
Lapique, EL
Massonnaud, CR
Belhadi, D
Jamard, S
Goehringer, F
Danion, F
Reignier, J
de Castro, N
Garot, D
Lacombe, K
Tolsma, V
Faure, E
Malvy, D
Staub, T
Courjon, J
Cazenave-Roblot, F
Dyrhol Riise, AM
Leturnier, P
Martin-Blondel, G
Roger, C
Akinosoglou, K
Moing, VL
Piroth, L
Sellier, P
Lescure, X
Trøseid, M
Clevenbergh, P
Dalgard, O
Gallien, S
Gousseff, M
Loubet, P
Vardon-Bounes, F
Visée, C
Belkhir, L
Botelho-Nevers, É
Cabié, A
Kotanidou, A
Lanternier, F
Rouveix-Nordon, E
Silva, S
Thiery, G
Poignard, P
Carcelain, G
Diallo, A
Mercier, N
Terzic, V
Bouscambert-Duchamp, M
Gaymard, A
Trabaud, MA
Destras, G
Josset, L
Billard, N
Han, TH
Guedj, J
Couffin-Cadiergues, S
Dechanet, A
Delmas, C
Esperou, H
Fougerou-Leurent, C
Mestre, SL
Métois, A
Noret, M
Bally, I
Dergan-Dylon, S
Tubiana, S
Kalif, O
Bergaud, N
Leveau, B
Eustace, J
Greil, R
Hajdu, E
Halanova, M
Paiva, JA
Piekarska, A||
Rodriguez Baño, J
Tonby, K
Trojánek, M
Tsiodras, S
Unal, S
Burdet, C
Costagliola, D
Yazdanpanah, Y
Peiffer-Smadja, N
Mentré, F
Ader, F
DisCoVeRy study group
Title: Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
Publisher: Elsevier
Issue Date: 2024
DOI: 10.1016/j.jinf.2024.106120
URI: https://hdl.handle.net/10216/157559
Source: J Infect. 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16.
Related Information: info:eu-repo/grantAgreement/EC/H2020/101015736/EU
Document Type: Outra Publicação em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Appears in Collections:ISPUP - Outra Publicação em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
hites-ji24-oprcio.pdf2.21 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons